Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196206 · ClinicalTrials.gov registry record · Phase 1
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
A Phase 1 study of Thrombosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT03196206 is a Phase 1 study of Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03196206, a Phase 1 study of Thrombosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
Conditions Studied
Interventions
- DRUG BMS-986177
Study Locations (3)
Florida
- Clinical Pharmacology Of Miami Inc. - Miami
- Clinical Pharmacology of Miami LLC - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2018-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03196206
The ClinicalTrials.gov registry entry for NCT03196206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which BMS-986177 is the first listed.
NCT03196206 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03196206 about?
NCT03196206 is a clinical study titled "Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment". Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
What is the current status of trial NCT03196206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-07-13. Estimated completion is 2018-03-04.
What conditions does trial NCT03196206 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT03196206?
The interventions under investigation include: BMS-986177 (DRUG).
Who is sponsoring clinical trial NCT03196206?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03196206 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
COMPLETED · Phase 1
-
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
COMPLETED · Phase 1
-
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
COMPLETED · Phase 1
-
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.